ESR1 and neoplasm: Similar to responses observed in vitro, birinapant did not impact on tumor growth of the PDX-315 ER+ model but significantly attenuated the growth of PDX-23 and all three TNBC models (PDX-110, -838, and -322), accompanied by significant improvement in survival to ethical endpoint (Fig. 2 and Supplementary Fig. 2).